Beam's BEAM-301 Shows Proof of Concept in GSDIa, Restoring Glucose Production
BEAM sits 26% above its 52-week low of $20.23.
Summary
Beam reported initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia (GSDIa), showing restoration of endogenous glucose production after a single treatment. Evaluable patients at the 40 mg dose achieved ≥15 hours of controlled fasting, and starch requirements were reduced. Safety was consistent with LNP therapies. This is the first clinical proof of concept for in vivo base editing in GSDIa, de-risking the platform and supporting a disease-modifying effect. The company will host an investor webcast on October 27 at 8:00 a.m. ET to discuss the data.
At the time of this announcement, BEAM was trading at $25.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $20.23 to $38.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.